Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach

References

• Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51(6):778–785. doi:10.1038/bmt.2016.1826901703
   PubMed Web of Science ®Google Scholar
• Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–1883. doi:10.1001/jama.2011.155822045765
   PubMed Web of Science ®Google Scholar
• Aljurf M, Weisdorf D, Alfraih F, et al. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries. Bone Marrow Transplant. 2019;54(8):1179–1188. doi:10.1038/s41409-019-0476-630778127
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.00518489989
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–2101. doi:10.1056/NEJMoa100438321105791
   PubMed Web of Science ®Google Scholar
• Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230–2239. doi:10.1200/JCO.2010.33.721221464398
   PubMed Web of Science ®Google Scholar
• Martin PJ, Counts GW Jr., Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011–1016. doi:10.1200/JCO.2009.25.669320065176
   PubMed Web of Science ®Google Scholar
• Syrjala KL, Martin PJ, Lee SJ. Delivering care to long-term adult survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30(30):3746–3751. doi:10.1200/JCO.2012.42.303823008296
   PubMed Web of Science ®Google Scholar
• Sun CL, Francisco L, Kawashima T, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood. 2010;116(17):3129–3139; quiz 3377. doi:10.1182/blood-2009-06-229369
   Web of Science ®Google Scholar
• Chow EJ, Cushing-Haugen KL, Cheng G-S, et al. Morbidity and mortality differences between hematopoietic cell transplantation survivors and other cancer survivors. J Clin Oncol. 2017;35(3):306–313. doi:10.1200/JCO.2016.68.845727870568
   PubMed Web of Science ®Google Scholar
• Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30(1):71–77. doi:10.1200/JCO.2011.38.459422147737
   PubMed Web of Science ®Google Scholar
• Amler S, Sauerland MC, Deiters C, Buchner T, Schumacher A. Factors influencing life satisfaction in acute myeloid leukemia survivors following allogeneic stem cell transplantation: a cross-sectional study. Health Qual Life Outcomes. 2015;13:28. doi:10.1186/s12955-015-0222-825888906
   PubMed Web of Science ®Google Scholar
• Jeon M, Yoo IY, Kim S, Lee J. Post-traumatic growth in survivors of allogeneic hematopoietic stem cell transplantation. Psychooncology. 2015;24(8):871–877. doi:10.1002/pon.372425382562
   PubMed Web of Science ®Google Scholar
• Majhail NS, Rizzo JD. Surviving the cure: long term followup of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2013;48(9):1145–1151. doi:10.1038/bmt.2012.25823292238
   PubMed Web of Science ®Google Scholar
• Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3(7):961–968. doi:10.1001/jamaoncol.2016.691428253393
   PubMed Web of Science ®Google Scholar
• Oberoi S, Robinson PD, Cataudella D, et al. Physical activity reduces fatigue in patients with cancer and hematopoietic stem cell transplant recipients: a systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol. 2018;122:52–59. doi:10.1016/j.critrevonc.2017.12.01129458789
   PubMed Web of Science ®Google Scholar
• Li Z, Mewawalla P, Stratton P, et al. Sexual health in hematopoietic stem cell transplant recipients. Cancer. 2015;121(23):4124–4131. doi:10.1002/cncr.2967526372459
   PubMed Web of Science ®Google Scholar
• Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol. 2006;24(30):4882–4887. doi:10.1200/JCO.2006.06.827017050873
   PubMed Web of Science ®Google Scholar
• Andrykowski MA, Bishop MM, Hahn EA, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol. 2005;23(3):599–608. doi:10.1200/JCO.2005.03.18915659507
   PubMed Web of Science ®Google Scholar
• Baker F, Zabora J, Polland A, Wingard J. Reintegration after bone marrow transplantation. Cancer Pract. 1999;7(4):190–197. doi:10.1046/j.1523-5394.1999.74005.x10687584
   PubMedGoogle Scholar
• Bergkvist K, Fossum B, Johansson UB, Mattsson J, Larsen J. Patients’ experiences of different care settings and a new life situation after allogeneic haematopoietic stem cell transplantation. Eur J Cancer Care (Engl). 2018;27(5):1. doi:10.1111/ecc.12868
   Web of Science ®Google Scholar
• Bevans M, El-Jawahri A, Tierney DK, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the patient-centered outcomes working group report. Biol Blood Marrow Transplant. 2017;23(4):538–551. doi:10.1016/j.bbmt.2016.09.01127660168
   PubMed Web of Science ®Google Scholar
• Peric Z, Desnica L, Durakovic N, et al. Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease? Croat Med J. 2016;57(1):6–15. doi:10.3325/cmj.2016.57.626935610
   PubMed Web of Science ®Google Scholar
• Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(1):7–19. doi:10.1182/blood-2008-10-18259219336756
   PubMed Web of Science ®Google Scholar
• Watson M, Zittoun R, Hall E, Solbu G, Wheatley K. A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: the MRC/EORTC QLQ-LEU. Qual Life Res. 1996;5(1):15–19. doi:10.1007/BF004359648901362
   PubMed Web of Science ®Google Scholar
• McQuellon RP, Russell GB, Cella DF, et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant. 1997;19(4):357–368. doi:10.1038/sj.bmt.17006729051246
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE Jr., Raczek AE, The MOS. 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–263. doi:10.1097/00005650-199303000-000068450681
   PubMed Web of Science ®Google Scholar
• Hashmi S, Carpenter P, Khera N, Tichelli A, Savani BN. Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors. Biol Blood Marrow Transplant. 2015;21(2):225–232. doi:10.1016/j.bbmt.2014.06.03524999225
   PubMed Web of Science ®Google Scholar
• Kenyon M, Babic A. The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT. 2018.
   Google Scholar
• Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(3):337–341. doi:10.1038/bmt.2012.522395764
   PubMed Web of Science ®Google Scholar
• Vetsch J, Fardell JE, Wakefield CE, et al. “Forewarned and forearmed”: long-term childhood cancer survivors’ and parents’ information needs and implications for survivorship models of care. Patient Educ Couns. 2017;100(2):355–363. doi:10.1016/j.pec.2016.09.01327693083
   PubMed Web of Science ®Google Scholar
• Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30–37. doi:10.1182/blood-2016-07-68664227821503
   PubMed Web of Science ®Google Scholar
• Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(2):211–234. doi:10.1016/j.bbmt.2016.09.02327713092
   PubMed Web of Science ®Google Scholar
• Armenian SH, Chemaitilly W, Chen M, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the cardiovascular disease and associated risk factors working group report. Biol Blood Marrow Transplant. 2017;23(2):201–210. doi:10.1016/j.bbmt.2016.08.01927590105
   PubMed Web of Science ®Google Scholar
• Armenian SH, Chow EJ. Cardiovascular disease in survivors of hematopoietic cell transplantation. Cancer. 2014;120(4):469–479. doi:10.1002/cncr.2844424166350
   PubMed Web of Science ®Google Scholar
• Armenian SH, Sun CL, Francisco L, et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol. 2008;26(34):5537–5543. doi:10.1200/JCO.2008.17.742818809605
   PubMed Web of Science ®Google Scholar
• Armenian SH, Sun CL, Mills G, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16(8):1138–1144. doi:10.1016/j.bbmt.2010.02.02120197101
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Cochran TR, Franco VI, Miller TL. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol. 2013;10(12):697–710. doi:10.1038/nrclinonc.2013.19524165948
   PubMed Web of Science ®Google Scholar
• Chow EJ, Wong K, Lee SJ, et al. Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(6):794–800. doi:10.1016/j.bbmt.2014.02.01224565992
   PubMed Web of Science ®Google Scholar
• Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002;359(9323):2078–2083. doi:10.1016/S0140-6736(02)08907-912086762
   PubMed Web of Science ®Google Scholar
• Felicetti F, Fortunati N, Brignardello E. Cancer survivors: an expanding population with an increased cardiometabolic risk. Diabetes Res Clin Pract. 2018;143:432–442. doi:10.1016/j.diabres.2018.02.01629475020
   PubMed Web of Science ®Google Scholar
• Felicetti F, D’Ascenzo F, Moretti C, et al. Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry. Eur J Prev Cardiol. 2015;22(6):762–770. doi:10.1177/204748731452934824691151
   PubMed Web of Science ®Google Scholar
• Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110(9):3463–3471. doi:10.1182/blood-2006-10-05408017664354
   PubMed Web of Science ®Google Scholar
• Fuji S, Takano K, Mori T, et al. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49(12):1505–1512. doi:10.1038/bmt.2014.17825111511
   PubMed Web of Science ®Google Scholar
• Lu CW, Yang KC, Chang HH, Lee LT, Chen CY, Huang KC. Sarcopenic obesity is closely associated with metabolic syndrome. Obes Res Clin Pract. 2013;7(4):e301–307. doi:10.1016/j.orcp.2012.02.00324306159
   PubMed Web of Science ®Google Scholar
• Mostoufi-Moab S, Ginsberg JP, Bunin N, et al. Body composition abnormalities in long-term survivors of pediatric hematopoietic stem cell transplantation. J Pediatr. 2012;160(1):122–128. doi:10.1016/j.jpeds.2011.06.04121839468
   PubMed Web of Science ®Google Scholar
• Greenfield DM, Boland E, Ezaydi Y, et al. Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Bone Marrow Transplant. 2014;49(7):907–912. doi:10.1038/bmt.2014.6324710566
   PubMed Web of Science ®Google Scholar
• Baker KS, Chow E, Steinberger J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(5):619–625. doi:10.1038/bmt.2011.11821643022
   PubMed Web of Science ®Google Scholar
• Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007;109(4):1765–1772. doi:10.1182/blood-2006-05-02233517047152
   PubMed Web of Science ®Google Scholar
• Blaser BW, Kim HT, Alyea EP 3rd, et al. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(4):575–583. doi:10.1016/j.bbmt.2011.08.00321839706
   PubMed Web of Science ®Google Scholar
• Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009;43(1):49–54. doi:10.1038/bmt.2008.26318724397
   PubMed Web of Science ®Google Scholar
• Chow EJ, Baker KS, Lee SJ, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014;32(3):191–198. doi:10.1200/JCO.2013.52.658224297944
   PubMed Web of Science ®Google Scholar
• Marini BL, Choi SW, Byersdorfer CA, Cronin S, Frame DG. Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2015;21(5):809–820. doi:10.1016/j.bbmt.2014.10.02725459644
   PubMed Web of Science ®Google Scholar
• Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood. 2010;116(8):1197–1204. doi:10.1182/blood-2010-03-27657620439623
   PubMed Web of Science ®Google Scholar
• Fuji S, Rovo A, Ohashi K, et al. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. Bone Marrow Transplant. 2016;51(8):1041–1049. doi:10.1038/bmt.2016.8127042848
   PubMed Web of Science ®Google Scholar
• Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(9):1100–1107. doi:10.1016/j.bbmt.2009.05.01019660723
   PubMed Web of Science ®Google Scholar
• Pophali PA, Klotz JK, Ito S, et al. Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Exp Hematol. 2014;42(2):83–89. doi:10.1016/j.exphem.2013.07.00324141092
   PubMed Web of Science ®Google Scholar
• Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–939. doi:10.1016/j.echo.2014.07.01225172399
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801. doi:10.1093/eurheartj/ehw21127567406
   PubMed Web of Science ®Google Scholar
• Armenian SH, Ryan TD, Khouri MG. Cardiac dysfunction and heart failure in hematopoietic cell transplantation survivors: emerging paradigms in pathophysiology, screening, and prevention. Heart Fail Clin. 2017;13(2):337–345. doi:10.1016/j.hfc.2016.12.00828279419
   PubMed Web of Science ®Google Scholar
• Chueh HW, Yoo JH. Metabolic syndrome induced by anticancer treatment in childhood cancer survivors. Ann Pediatr Endocrinol Metab. 2017;22(2):82–89. doi:10.6065/apem.2017.22.2.8228690985
   PubMed Web of Science ®Google Scholar
• Greenfield DMSJ. Cardiovascular Diseases and Metabolic Syndrome. The EBMT Handbook - Hematopoietic Stem Cell Transplantation and Cellular Therapies E Carreras, C Dufour, M Mohty, N Kroger Editors. In: Vol The EBMT Handbook - Hematopoietic Stem Cell Transplantation and Cellular Therapies; 2019.
   Google Scholar
• Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102(4):614–625. doi:10.3324/haematol.2016.15025028232372
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956. doi:10.1016/j.bbmt.2005.09.00416338616
   PubMed Web of Science ®Google Scholar
• Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S106–114. doi:10.1016/j.bbmt.2009.11.00219896545
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401 e381. doi:10.1016/j.bbmt.2014.12.00125529383
   PubMed Web of Science ®Google Scholar
• Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(7):749–759. doi:10.1016/j.bbmt.2007.05.00117580252
   PubMed Web of Science ®Google Scholar
• Lee KS, Kullnig P, Hartman TE, Muller NL. Cryptogenic organizing pneumonia: CT findings in 43 patients. AJR Am J Roentgenol. 1994;162(3):543–546. doi:10.2214/ajr.162.3.81094938109493
   PubMed Web of Science ®Google Scholar
• Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood. 2003;102(10):3822–3828. doi:10.1182/blood-2002-06-181312869516
   PubMed Web of Science ®Google Scholar
• Williams KM, Cheng GS, Pusic I, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):710–716. doi:10.1016/j.bbmt.2015.10.00926475726
   PubMed Web of Science ®Google Scholar
• Huang TT, Hudson MM, Stokes DC, Krasin MJ, Spunt SL, Ness KK. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest. 2011;140(4):881–901. doi:10.1378/chest.10-213321415131
   PubMed Web of Science ®Google Scholar
• Limper AH. Chemotherapy-induced lung disease. Clin Chest Med. 2004;25(1):53–64. doi:10.1016/S0272-5231(03)00123-015062597
   PubMed Web of Science ®Google Scholar
• Brignardello E, Felicetti F, Castiglione A, et al. Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinics. Eur J Endocrinol. 2013;168(3):465–472. doi:10.1530/EJE-12-104323258270
   PubMed Web of Science ®Google Scholar
• Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the childhood cancer survivor study cohort: a review of published findings. J Clin Oncol. 2009;27(14):2339–2355. doi:10.1200/JCO.2008.21.195319364955
   PubMed Web of Science ®Google Scholar
• Felicetti F, Manicone R, Corrias A, et al. Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: a retrospective study from a single institution. J Cancer Res Clin Oncol. 2011;137(9):1343–1348. doi:10.1007/s00432-011-1004-221769505
   PubMed Web of Science ®Google Scholar
• Oudin C, Auquier P, Bertrand Y, et al. Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study. Haematologica. 2016;101(6):747–756. doi:10.3324/haematol.2015.14005326969082
   PubMed Web of Science ®Google Scholar
• Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years’ experience. Blood. 2009;113(2):306–308. doi:10.1182/blood-2008-08-17300518838614
   PubMed Web of Science ®Google Scholar
• Tatevossian R, Blair JC, Plowman PN, Savage MO, Shankar AG. Thyrotoxicosis after matched unrelated bone marrow transplantation. J Pediatr Hematol Oncol. 2004;26(8):529–531. doi:10.1097/01.mph.0000132937.73264.5515284594
   PubMed Web of Science ®Google Scholar
• Clement SC, Kremer LCM, Verburg FA, et al. Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Cancer Treat Rev. 2018;63:28–39. doi:10.1016/j.ctrv.2017.11.00529202445
   PubMed Web of Science ®Google Scholar
• Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res. 2010;174(6):741–752. doi:10.1667/RR2240.121128798
   PubMed Web of Science ®Google Scholar
• Brignardello E, Felicetti F, Castiglione A, et al. Ultrasound surveillance for radiation-induced thyroid carcinoma in adult survivors of childhood cancer. Eur J Cancer. 2016;55:74–80. doi:10.1016/j.ejca.2015.12.00626775213
   PubMed Web of Science ®Google Scholar
• Gallo M, Felicetti F, Brignardello E. Thyroid cancer in cancer survivors: the role of ultrasound and the need for committed specialists. Am J Med. 2014;127(4):e11. doi:10.1016/j.amjmed.2013.10.021
   Web of Science ®Google Scholar
• Chemaitilly W, Li Z, Huang S, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol. 2015;33(5):492–500. doi:10.1200/JCO.2014.56.793325559807
   PubMed Web of Science ®Google Scholar
• Kauppila M, Koskinen P, Irjala K, Remes K, Viikari J. Long-term effects of allogeneic bone marrow transplantation (BMT) on pituitary, gonad, thyroid and adrenal function in adults. Bone Marrow Transplant. 1998;22(4):331–337. doi:10.1038/sj.bmt.17013379722067
   PubMed Web of Science ®Google Scholar
• Vantyghem M-C, Cornillon J, Decanter C, et al. Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation. Orphanet J Rare Dis. 2014;9(1):162. doi:10.1186/s13023-014-0162-025496809
   PubMed Web of Science ®Google Scholar
• Lehmann V, Nahata L, Ferrante AC, et al. Fertility-related perceptions and impact on romantic relationships among adult survivors of childhood cancer. J Adolesc Young Adult Oncol. 2018;7(4):409–414. doi:10.1089/jayao.2017.012129466084
   PubMed Web of Science ®Google Scholar
• Crawshaw M. Psychosocial oncofertility issues faced by adolescents and young adults over their lifetime: a review of the research. Hum Fertil (Camb). 2013;16(1):59–63. doi:10.3109/14647273.2012.73348023009083
   PubMed Web of Science ®Google Scholar
• Brignardello E, Felicetti F, Castiglione A, et al. Gonadal status in long-term male survivors of childhood cancer. J Cancer Res Clin Oncol. 2016;142(5):1127–1132. doi:10.1007/s00432-016-2124-526860726
   PubMed Web of Science ®Google Scholar
• Barton SE, Najita JS, Ginsburg ES, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013;14(9):873–881. doi:10.1016/S1470-2045(13)70251-123856401
   PubMed Web of Science ®Google Scholar
• Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod. 2003;18(1):117–121. doi:10.1093/humrep/deg01612525451
   PubMed Web of Science ®Google Scholar
• van der Kaaij MA, Heutte N, Meijnders P, et al. Premature ovarian failure and fertility in long-term survivors of Hodgkin’s lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d’Etude des Lymphomes de l’Adulte Cohort Study. J Clin Oncol. 2012;30(3):291–299. doi:10.1200/JCO.2011.37.198922184372
   PubMed Web of Science ®Google Scholar
• Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin’s disease. Cancer. 1983;52(6):988–993. doi:10.1002/1097-0142(19830915)52:6<988::AID-CNCR2820520610>3.0.CO;2-66411321
   PubMed Web of Science ®Google Scholar
• Shalet SM, Tsatsoulis A, Whitehead E, Read G. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J Endocrinol. 1989;120(1):161–165. doi:10.1677/joe.0.12001612493061
   PubMed Web of Science ®Google Scholar
• Wallace WH, Shalet SM, Lendon M, Morris-Jones PH. Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia. Int J Androl. 1991;14(5):312–319. doi:10.1111/j.1365-2605.1991.tb01098.x1794916
   PubMedGoogle Scholar
• Anderson RA, Mitchell RT, Kelsey TW, Spears N, Telfer EE, Wallace WH. Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults. Lancet Diabetes Endocrinol. 2015;3(7):556–567. doi:10.1016/S2213-8587(15)00039-X25873571
   PubMed Web of Science ®Google Scholar
• van Dorp W, Mulder RL, Kremer LC, et al. Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the PanCareSurFup Consortium. J Clin Oncol. 2016;34(28):3440–3450. doi:10.1200/JCO.2015.64.328827458300
   PubMed Web of Science ®Google Scholar
• Skinner R, Mulder RL, Kremer LC, et al. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Lancet Oncol. 2017;18(2):e75–e90. doi:10.1016/S1470-2045(17)30026-828214419
   PubMed Web of Science ®Google Scholar
• Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril. 2013;100(5):1180–1186. doi:10.1016/j.fertnstert.2013.08.01024012199
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Ghamdi A, Al-Mohareb F, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmology. 2009;116(9):1624–1629. doi:10.1016/j.ophtha.2009.04.05419729097
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Chai X, Kurland BF, et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology. 2012;119(3):487–493. doi:10.1016/j.ophtha.2011.08.04022153706
   PubMed Web of Science ®Google Scholar
• Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013;58(3):233–251. doi:10.1016/j.survophthal.2012.08.00423541042
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Flournoy N, Sullivan KM, et al. Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys. 1984;10(7):957–964. doi:10.1016/0360-3016(84)90163-96378850
   PubMed Web of Science ®Google Scholar
• Giri N, Davis EA, Vowels MR. Long-term complications following bone marrow transplantation in children. J Paediatr Child Health. 1993;29(3):201–205. doi:10.1111/j.1440-1754.1993.tb00487.x8518003
   PubMed Web of Science ®Google Scholar
• Gurney JG, Ness KK, Rosenthal J, Forman SJ, Bhatia S, Baker KS. Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study. Cancer. 2006;106(6):1402–1408. doi:10.1002/cncr.2175216453335
   PubMed Web of Science ®Google Scholar
• Belkacemi Y, Labopin M, Vernant JP, et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys. 1998;41(3):659–668. doi:10.1016/S0360-3016(98)00077-79635717
   PubMed Web of Science ®Google Scholar
• Atilla E, Atilla PA, Toprak SK, Demirer T. A review of late complications of allogeneic hematopoietic stem cell transplantations. Clin Transplant. 2017;31:10. doi:10.1111/ctr.13062
   Web of Science ®Google Scholar
• Woo SB, Lee SJ, Schubert MM. Graft-vs.-host disease. Crit Rev Oral Biol Med. 1997;8(2):201–216. doi:10.1177/104544119700800207019167093
   PubMedGoogle Scholar
• Alborghetti MR, Correa ME, Adam RL, et al. Late effects of chronic graft-vs.-host disease in minor salivary glands. J Oral Pathol Med. 2005;34(8):486–493. doi:10.1111/j.1600-0714.2005.00347.x16091116
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Schubert MM, Flowers ME. Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12(7):792–794. doi:10.1016/j.bbmt.2006.03.01016785070
   PubMed Web of Science ®Google Scholar
• Treister N, Duncan C, Cutler C, Lehmann L. How we treat oral chronic graft-versus-host disease. Blood. 2012;120(17):3407–3418. doi:10.1182/blood-2012-05-39338922898605
   PubMed Web of Science ®Google Scholar
• Farahani M, Eichmiller FC, McLaughlin WL. Measurement of absorbed doses near metal and dental material interfaces irradiated by x- and gamma-ray therapy beams. Phys Med Biol. 1990;35(3):369–385. doi:10.1088/0031-9155/35/3/0062320667
   PubMed Web of Science ®Google Scholar
• Boer CC, Correa ME, Miranda EC, de Souza CA. Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45(4):705–711. doi:10.1038/bmt.2009.23719767788
   PubMed Web of Science ®Google Scholar
• Ferry C, Gemayel G, Rocha V, et al. Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplant. 2007;40(3):219–224. doi:10.1038/sj.bmt.170571017530002
   PubMed Web of Science ®Google Scholar
• Vesterbacka M, Ringden O, Remberger M, Huggare J, Dahllof G. Disturbances in dental development and craniofacial growth in children treated with hematopoietic stem cell transplantation. Orthod Craniofac Res. 2012;15(1):21–29. doi:10.1111/j.1601-6343.2011.01533.x22264324
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175–1183. doi:10.1182/blood-2008-05-15878218971419
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Shah NN, Savani BN, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(8):1013–1023. doi:10.1038/bmt.2015.6325822223
   PubMed Web of Science ®Google Scholar
• Atsuta Y, Suzuki R, Yamashita T, et al. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol. 2014;25(2):435–441. doi:10.1093/annonc/mdt55824399081
   PubMed Web of Science ®Google Scholar
• Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood. 2009;113(17):4114–4124. doi:10.1182/blood-2008-09-17792319168787
   PubMed Web of Science ®Google Scholar
• Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer. 2008;113(7):1580–1587. doi:10.1002/cncr.2377318704986
   PubMed Web of Science ®Google Scholar
• Clavert A, Peric Z, Brissot E, et al. Late complications and quality of life after reduced-intensity conditioning allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(1):140–146. doi:10.1016/j.bbmt.2016.10.01127751934
   PubMed Web of Science ®Google Scholar
• Hingorani S. Renal complications of hematopoietic-cell transplantation. N Engl J Med. 2016;374(23):2256–2267. doi:10.1056/NEJMra140471127276563
   PubMed Web of Science ®Google Scholar
• Hingorani S, Guthrie KA, Schoch G, Weiss NS, McDonald GB. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant. 2007;39(4):223–229. doi:10.1038/sj.bmt.170557317290279
   PubMed Web of Science ®Google Scholar
• Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14(6):658–663. doi:10.1016/j.bbmt.2008.03.00818489991
   PubMed Web of Science ®Google Scholar
• Delgado J, Cooper N, Thomson K, et al. The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12(1):75–83. doi:10.1016/j.bbmt.2005.08.03616399571
   PubMed Web of Science ®Google Scholar
• Verghese PS, Finn LS, Englund JA, Sanders JE, Hingorani SR. BK nephropathy in pediatric hematopoietic stem cell transplant recipients. Pediatr Transplant. 2009;13(7):913–918. doi:10.1111/j.1399-3046.2008.01069.x19067914
   PubMed Web of Science ®Google Scholar
• Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(8):571–575. doi:10.1016/j.bbmt.2005.06.00116041306
   PubMed Web of Science ®Google Scholar
• Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95–100. doi:10.3324/haematol.1069917229640
   PubMed Web of Science ®Google Scholar
• Colombo AA, Rusconi C, Esposito C, et al. Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease. Transplantation. 2006;81(8):1087–1092. doi:10.1097/01.tp.0000209496.26639.cb16641591
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Balow JE, Sabnis S, et al. Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol. 2005;131(1):74–79. doi:10.1111/j.1365-2141.2005.05728.x16173966
   PubMed Web of Science ®Google Scholar
• Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B. Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease? Clin J Am Soc Nephrol. 2006;1(4):685–694. doi:10.2215/CJN.0038070517699273
   PubMed Web of Science ®Google Scholar
• Rao PS. Nephrotic syndrome in patients with peripheral blood stem cell transplant. Am J Kidney Dis. 2005;45(4):780–785. doi:10.1053/j.ajkd.2005.01.00315806483
   PubMed Web of Science ®Google Scholar
• Terrier B, Delmas Y, Hummel A, et al. Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects. Nephrol Dialysis Transplant. 2007;22(5):1369–1376. doi:10.1093/ndt/gfl795
   Web of Science ®Google Scholar
• Weiss AS, Sandmaier BM, Storer B, Storb R, McSweeney PA, Parikh CR. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant. 2006;6(1):89–94. doi:10.1111/j.1600-6143.2005.01131.x16433761
   PubMed Web of Science ®Google Scholar
• Frisk P, Bratteby LE, Carlson K, Lonnerholm G. Renal function after autologous bone marrow transplantation in children: a long-term prospective study. Bone Marrow Transplant. 2002;29(2):129–136. doi:10.1038/sj.bmt.170331211850707
   PubMed Web of Science ®Google Scholar
• Miralbell R, Bieri S, Mermillod B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14(2):579–585. doi:10.1200/JCO.1996.14.2.5798636774
   PubMed Web of Science ®Google Scholar
• Chang A, Hingorani S, Kowalewska J, et al. Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature. Clin J Am Soc Nephrol. 2007;2(5):1014–1023. doi:10.2215/CJN.0170040717702721
   PubMed Web of Science ®Google Scholar
• Nieto Y, Russ P, Everson G, et al. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2000;26(1):109–111. doi:10.1038/sj.bmt.170247110918414
   PubMed Web of Science ®Google Scholar
• Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation. 2003;75(5):665–672. doi:10.1097/01.TP.0000053753.43268.F012640307
   PubMed Web of Science ®Google Scholar
• Sakai M, Strasser SI, Shulman HM, McDonald SJ, Schoch HG, McDonald GB. Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome. Bone Marrow Transplant. 2009;44(7):441–447. doi:10.1038/bmt.2009.5619308033
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103(5):1618–1624. doi:10.1182/blood-2003-06-214514576071
   PubMed Web of Science ®Google Scholar
• Picardi M, De Rosa G, Selleri C, Pane F, Rotoli B, Muretto P. Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for hematological malignancies. Transplantation. 2006;82(1):141–142. doi:10.1097/01.tp.0000225828.27850.fc16861957
   PubMed Web of Science ®Google Scholar
• Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood. 1999;93(10):3259–3266. doi:10.1182/blood.V93.10.3259.410k13_3259_326610233877
   PubMed Web of Science ®Google Scholar
• Giaccone L, Festuccia M, Marengo A, et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(6):809–817. doi:10.1016/j.bbmt.2009.12.53320060484
   PubMed Web of Science ®Google Scholar
• Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113(14):3147–3153. doi:10.1182/blood-2008-10-16349319144986
   PubMed Web of Science ®Google Scholar
• McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51(4):1450–1460. doi:10.1002/hep.2353320373370
   PubMed Web of Science ®Google Scholar
• Majhail NS, Lazarus HM, Burns LJ. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2010;16(6):832–837. doi:10.1016/j.bbmt.2010.01.00420079863
   PubMed Web of Science ®Google Scholar
• Shenoy S, Angelucci E, Arnold SD, et al. Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(4):552–561. doi:10.1016/j.bbmt.2017.01.00928065838
   PubMed Web of Science ®Google Scholar
• Rose C, Ernst O, Hecquet B, et al. Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica. 2007;92(6):850–853. doi:10.3324/haematol.1106317550861
   PubMed Web of Science ®Google Scholar
• Meyer SC, O’Meara A, Buser AS, Tichelli A, Passweg JR, Stern M. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(3):440–444. doi:10.1016/j.bbmt.2012.10.01223089566
   PubMed Web of Science ®Google Scholar
• Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100(1):17–21. doi:10.1182/blood.V100.1.1712070002
   PubMed Web of Science ®Google Scholar
• Madden LM, Hayashi RJ, Chan KW, et al. Long-term follow-up after reduced-intensity conditioning and stem cell transplantation for childhood nonmalignant disorders. Biol Blood Marrow Transplant. 2016;22(8):1467–1472. doi:10.1016/j.bbmt.2016.04.02527164064
   PubMed Web of Science ®Google Scholar
• Farmakis D, Triposkiadis F, Lekakis J, Parissis J. Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management. Eur J Heart Fail. 2017;19(4):479–489. doi:10.1002/ejhf.70828000341
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Virtanen JM, et al. Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant. 2014;20(8):1248–1251. doi:10.1016/j.bbmt.2014.04.02424769316
   PubMed Web of Science ®Google Scholar
• Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood. 2013;122(9):1678–1684. doi:10.1182/blood-2013-04-49977223777771
   PubMed Web of Science ®Google Scholar
• Savani BN, Griffith ML, Jagasia S, Lee SJ. How I treat late effects in adults after allogeneic stem cell transplantation. Blood. 2011;117(11):3002–3009. doi:10.1182/blood-2010-10-26309521193694
   PubMed Web of Science ®Google Scholar
• Maffini E, Festuccia M, Brunello L, Boccadoro M, Giaccone L, Bruno B. Neurologic complications after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(3):388–397. doi:10.1016/j.bbmt.2016.12.63228039081
   PubMed Web of Science ®Google Scholar
• Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003;63(15):1549–1563. doi:10.2165/00003495-200363150-0000312887262
   PubMed Web of Science ®Google Scholar
• Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep. 1986;70(10):1225–1228.2428492
   PubMedGoogle Scholar
• Merkel DE, Griffin NL, Kagan-Hallet K, Von Hoff DD. Central nervous system toxicity with fludarabine. Cancer Treat Rep. 1986;70(12):1449–1450.2431775
   PubMedGoogle Scholar
• Warrell RP Jr., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4(1):74–79. doi:10.1200/JCO.1986.4.1.742416889
   PubMed Web of Science ®Google Scholar
• Annaloro C, Costa A, Fracchiolla NS, et al. Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report. Clin Case Rep. 2015;3(7):650–655. doi:10.1002/ccr3.30826273463
   PubMedGoogle Scholar
• Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(3):300–308. doi:10.1016/j.bbmt.2010.04.00320399878
   PubMed Web of Science ®Google Scholar
• Moore-Maxwell CA, Datto MB, Hulette CM. Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies. Mod Pathol. 2004;17(2):241–247. doi:10.1038/modpathol.380004914704718
   PubMed Web of Science ®Google Scholar
• Soffietti R, Trevisan E, Ruda R. Neurologic complications of chemotherapy and other newer and experimental approaches. Handb Clin Neurol. 2014;121:1199–1218.24365412
   PubMedGoogle Scholar
• Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986;46(11):5953–5958.2428488
   PubMed Web of Science ®Google Scholar
• Reece DE, Frei-Lahr DA, Shepherd JD, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant. 1991;8(5):393–401.1768975
   PubMed Web of Science ®Google Scholar
• Lamy C, Oppenheim C, Meder JF, Mas JL. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging. 2004;14(2):89–96. doi:10.1111/j.1552-6569.2004.tb00223.x15095552
   PubMed Web of Science ®Google Scholar
• Sudulagunta SR, Sodalagunta MB, Kumbhat M, Settikere Nataraju A. Posterior reversible encephalopathy syndrome(PRES). Oxf Med Case Rep. 2017;2017(4):omx011. doi:10.1093/omcr/omx011
   PubMedGoogle Scholar
• Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int. 2012;32(6):590–594. doi:10.3747/pdi.2012.0015223212858
   PubMed Web of Science ®Google Scholar
• Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc. 1991;23(6):3175–3178.1721398
   PubMed Web of Science ®Google Scholar
• Renard D, Gauthier T, Venetz JP, Buclin T, Kuntzer T. Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient. Clin Kidney J. 2012;5(4):323–326. doi:10.1093/ckj/sfs06725874089
   PubMedGoogle Scholar
• Wilson JR, Conwit RA, Eidelman BH, Starzl T, Abu-Elmagd K. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve. 1994;17(5):528–532. doi:10.1002/mus.8801705107512691
   PubMed Web of Science ®Google Scholar
• Schacht J, Talaska AE, Rybak LP. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken). 2012;295(11):1837–1850. doi:10.1002/ar.2257823045231
   PubMedGoogle Scholar
• Openshaw H. Peripheral neuropathy after bone marrow transplantation. Biol Blood Marrow Transplant. 1997;3(4):202–209.9360782
   PubMedGoogle Scholar
• Kraus PD, Wolff D, Grauer O, et al. Muscle cramps and neuropathies in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease. PLoS One. 2012;7(9):e44922. doi:10.1371/journal.pone.004492223028681
   PubMed Web of Science ®Google Scholar
• Ruggiu M, Cuccuini W, Mokhtari K, et al. Case report: central nervous system involvement of human graft versus host disease: report of 7 cases and a review of literature. Medicine (Baltimore). 2017;96(42):e8303. doi:10.1097/MD.000000000000830329049232
   PubMed Web of Science ®Google Scholar
• Jim HS, Small B, Hartman S, et al. Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation. Cancer. 2012;118(13):3407–3416. doi:10.1002/cncr.2664522139882
   PubMed Web of Science ®Google Scholar
• Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. 2011;29(17):2397–2404. doi:10.1200/JCO.2010.33.911921537032
   PubMed Web of Science ®Google Scholar
• Buchbinder D, Kelly DL, Duarte RF, et al. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018;53(5):535–555. doi:10.1038/s41409-017-0055-729343837
   PubMed Web of Science ®Google Scholar
• Sharafeldin N, Bosworth A, Patel SK, et al. Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: results from a prospective longitudinal study. J Clin Oncol. 2018;36(5):463–475. doi:10.1200/JCO.2017.74.227029252122
   PubMed Web of Science ®Google Scholar
• Hoogland AI, Nelson AM, Small BJ, et al. The role of age in neurocognitive functioning among adult allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2017;23(11):1974–1979. doi:10.1016/j.bbmt.2017.08.00628797784
   PubMed Web of Science ®Google Scholar
• Kenyon M, Murray J, Quinn B, Greenfield D, Trigoso E. Late effects and long-term follow-up In: Kenyon M, Babic A, editors. The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT. Cham (CH); 2018:271–299.
   Google Scholar
• Mehta RS, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence. 2016;7(8):901–916. doi:10.1080/21505594.2016.120886627385018
   PubMed Web of Science ®Google Scholar
• Ogonek J, Kralj Juric M, Ghimire S, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:507. doi:10.3389/fimmu.2016.0050727909435
   PubMed Web of Science ®Google Scholar
• Mackall CL, Granger L, Sheard MA, Cepeda R, Gress RE. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood. 1993;82(8):2585–2594. doi:10.1182/blood.V82.8.2585.25857691265
   PubMed Web of Science ®Google Scholar
• Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all repertoires are not created equal. Immunol Today. 1997;18(5):245–251. doi:10.1016/S0167-5699(97)81664-79153957
   PubMedGoogle Scholar
• Dumont-Girard F, Roux E, van Lier RA, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood. 1998;92(11):4464–4471. doi:10.1182/blood.V92.11.44649834254
   PubMed Web of Science ®Google Scholar
• Weinberg K, Annett G, Kashyap A, Lenarsky C, Forman SJ, Parkman R. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol Blood Marrow Transplant. 1995;1(1):18–23.9118285
   PubMedGoogle Scholar
• Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995;332(3):143–149. doi:10.1056/NEJM1995011933203037800006
   PubMed Web of Science ®Google Scholar
• Gaballa A, Norberg A, Stikvoort A, et al. Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients. Bone Marrow Transplant. 2018;53(1):69–77. doi:10.1038/bmt.2017.21628991250
   PubMed Web of Science ®Google Scholar
• Saglio F, Cena S, Berger M, et al. Association between thymic function and allogeneic hematopoietic stem cell transplantation outcome: results of a pediatric study. Biol Blood Marrow Transplant. 2015;21(6):1099–1105. doi:10.1016/j.bbmt.2015.02.01025708218
   PubMed Web of Science ®Google Scholar
• Lia G, Butera S, Evangelista A, et al. Long-term thymic function and reconstitution of the T cell compartment after T cell-replete haplo-identical allografting. Biol Blood Marrow Transplant. 2019;25(3):S331. doi:10.1016/j.bbmt.2018.12.534
   Web of Science ®Google Scholar
• Storek J, Joseph A, Espino G, et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood. 2001;98(13):3505–3512. doi:10.1182/blood.V98.13.350511739150
   PubMed Web of Science ®Google Scholar
• Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant. 2007;13(11):1304–1312. doi:10.1016/j.bbmt.2007.07.00717950917
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–1238. doi:10.1016/j.bbmt.2009.06.01919747629
   PubMed Web of Science ®Google Scholar
• Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736–1754. doi:10.1161/CIRCULATIONAHA.106.18309517446442
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–4366. doi:10.1182/blood-2002-05-149612393425
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Einarsdottir S, Cesaro S, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e200–e212. doi:10.1016/S1473-3099(18)30600-530744963
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016;127(23):2824–2832. doi:10.1182/blood-2015-12-55047527048212
   PubMed Web of Science ®Google Scholar
• D’Souza AFC Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2018. 2018; https://www.cibmtr.org.
   Google Scholar
• Hosing C, Saliba RM, Shahjahan M, et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant. 2005;36(2):157–162. doi:10.1038/sj.bmt.170501115937511
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13(10):1160–1168. doi:10.1016/j.bbmt.2007.06.00717889352
   PubMed Web of Science ®Google Scholar
• Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19(2):464–471. doi:10.1200/JCO.2001.19.2.46411208840
   PubMed Web of Science ®Google Scholar
• Hasegawa W, Pond GR, Rifkind JT, et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2005;35(1):51–55. doi:10.1038/sj.bmt.170470615516939
   PubMed Web of Science ®Google Scholar
• Pole JD, Darmawikarta D, Gassas A, et al. Subsequent malignant neoplasms in pediatric cancer patients treated with and without hematopoietic SCT. Bone Marrow Transplant. 2015;50(5):721–726. doi:10.1038/bmt.2015.425706885
   PubMed Web of Science ®Google Scholar
• Shimoni A, Shem-Tov N, Chetrit A, et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced. Leukemia. 2013;27(4):829–835. doi:10.1038/leu.2012.29923072778
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Millard HR, Brazauskas R, et al. Survival and late effects after allogeneic hematopoietic cell transplantation for hematologic malignancy at less than three years of age. Biol Blood Marrow Transplant. 2017;23(8):1327–1334. doi:10.1016/j.bbmt.2017.04.01728461213
   PubMed Web of Science ®Google Scholar
• Heilmeier B, Stowasser N, Socie G, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation – follow up. Blood. 2008;112(11):453. doi:10.1182/blood.V112.11.453.45318650453
   PubMed Web of Science ®Google Scholar
• Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117(1):316–322. doi:10.1182/blood-2010-07-29462920926773
   PubMed Web of Science ®Google Scholar
• Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet. 2005;365(9476):2014–2023. doi:10.1016/S0140-6736(05)66695-015950715
   PubMed Web of Science ®Google Scholar
• Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105(10):3802–3811. doi:10.1182/blood-2004-09-341115687239
   PubMed Web of Science ®Google Scholar
• Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 1989;321(12):784–789. doi:10.1056/NEJM1989092132112032671734
   PubMed Web of Science ®Google Scholar
• Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001. doi:10.1182/blood-2008-09-17804619264919
   PubMed Web of Science ®Google Scholar
• Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101(5):2015–2023. doi:10.1182/blood-2002-04-126112393427
   PubMed Web of Science ®Google Scholar
• Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood. 2008;111(2):939–944. doi:10.1182/blood-2007-07-09928317911386
   PubMed Web of Science ®Google Scholar
• Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, Shaw BE. Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51(1):83–88. doi:10.1038/bmt.2015.20326367222
   PubMed Web of Science ®Google Scholar
• Hardy JM, Marguery MC, Huynh A, et al. Photo-induced graft-versus-host disease. Photodermatol Photoimmunol Photomed. 2016;32(5–6):291–295. doi:10.1111/phpp.1227327623188
   PubMed Web of Science ®Google Scholar
• Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95(23):1772–1783. doi:10.1093/jnci/djg10714652239
   PubMed Web of Science ®Google Scholar
• Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation–implications for screening and HPV vaccination. Biol Blood Marrow Transplant. 2008;14(9):1072–1075. doi:10.1016/j.bbmt.2008.07.00518721771
   PubMed Web of Science ®Google Scholar
• Tedeschi SK, Savani BN, Jagasia M, et al. Time to consider HPV vaccination after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(8):1033–1036. doi:10.1016/j.bbmt.2010.03.00720302962
   PubMed Web of Science ®Google Scholar
• Savani B. Blood and Marrow Transplantation Long‐Term Management: Prevention and Complications. Wiley-Blackwell; 2013.
   Google Scholar
• Shankar SM, Carter A, Sun CL, et al. Health care utilization by adult long-term survivors of hematopoietic cell transplant: report from the Bone Marrow Transplant Survivor Study. Cancer Epidemiol Biomarkers Prev. 2007;16(4):834–839. doi:10.1158/1055-9965.EPI-06-071417416780
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.880025113753
   PubMed Web of Science ®Google Scholar